The pharmaceutical industry is under intense pressure to reduce the environmental harm caused by drug development and manufacturing. Many companies have created new mandates for greener, more sustainable processes internally, and have extended those mandates to their CDMO partners. A few of these CDMOs are now at the forefront of green chemistry, applying its principles to reduce the environmental and human impact of pharmaceutical production.
Biotech companies need to think green as well. Most of the drugs coming to market today are acquired by large or mid-size pharma companies from small biotech companies. Partnering with a CDMO proficient in green chemistry and manufacturing can help a biotech create the most attractive drug package – one that includes a proven commercialization process minimizing toxic waste that pose safety concerns or require costly remediation